The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer

International Journal of Clinical Oncology

Volumn 18, Issue 1, 2013, Pages 26-32

  Duan, Xiao Feng ^a   Dong, Na Na ^a   Zhang, Ti ^a   Li, Qiang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Liver metastasis; Prognosis; Subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL FEATURE; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84874114298     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0336-x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Hao XS, Chen KS, Liu H (2002) Analysis of female breast cancer descriptive epidemiology in Tianjin, China. Asian Pac J Cancer Prev 3:143-148
3. Svetlovska D, Mardiak J (2005) Treatment strategy of early-stage breast cancer. Bratisl Lek Listy 106:362-365
4. Hess KR, Varadhachary GR, Taylor SH et al (2006) Metastatic patterns in adenocarcinoma. Cancer 106:1624-1633
5. Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897-907 (discussion 8)
6. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
7. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
8. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
9. Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114
10. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638-2645
11. Rodriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533-1539
12. Gao D, Du J, Cong L et al (2009) Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I-III of operable patients. Jpn J Clin Oncol 39:97-104
13. Heitz F, Harter P, Lueck HJ et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792-2798
14. Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942-948
15. Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10:R20
16. Anders CK, Deal AM, Miller CR et al (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117:1602-1611
17. Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
18. Ruers T, Bleichrodt RP (2002) Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38:1023-1033
19. Nicolini A, Giardino R, Carpi A et al (2006) Metastatic breast cancer: an updating. Biomed Pharmacother 60:548-556
20. Liu MT, Huang WT, Wang AY et al (2010) Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer 18:1553-1564
21. Goldhirsch A, Gelber RD, Castiglione M (1988) Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6:89-97
22. O'Reilly SM, Richards MA, Rubens RD (1990) Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26:574-577
23. Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89:284-290
24. Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830-835
25. Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652-5657
26. Chia SK, Speers CH, D'Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973-979
27. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502
28. Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518-524
29. Wang B, Guan ZZ, Liu DG et al (2004) Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer. Ai Zheng 23:1710-1713
30. Lower EE, Glass E, Blau R et al (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301-306